Abstract
This report provides a comprehensive analysis of Genzyme, Inc. It includes the
company' s organizational structure, description of its businesses and a vivid
account of its competitive landscape. This is bolstered by key insights on its
major competitors along with financial comparables. The study is conducted
against the backdrop emerging trends in biotech and its future growth drivers.
It highlights the current focus of teh company on bringing products to market
is driving the industry toward profitability. The report also explains
Genzyme' s inorganic growth path and strategic initiatives. Genzyme is
investing on restructuring and developing its manufacturing and R&D units
across the globe. It has built a new research center in the UK and is
improving quality at manufacturing facilities such as in Lyons. It is also
investing in research infrastructure in the US.
The US biotech industry is highly diversified, complex and fragmented with as
many as 14,370 units in operation. The industry is experiencing double-digit
growth along with consolidation, post the 2002 shakeout. Genzyme is the
fourth-largest biotech company in the world in revenue terms. The company has
performed strongly on the back of its successful R&D initiatives. The one
factor that clearly differentiates Genzyme from its peers is that around half
of its sales revenue came from outside the US. Genzyme' s revenue increased at
a CAGR of 30.87% over 2001-04. This was primarily on account of Renagel,
Fabrazyme and Cerezyme sales. To offset dependence on these drugs, the company
is now trying to grow inorganically by acquiring specialty in the oncology
space.
View Cart
